BP Drug Fights Deadly Superbug

A common blood pressure medication, Candesartan cilexetil, has emerged as a potential weapon against the highly resistant MRSA bacteria. Scientists discovered that this existing drug effectively disrupts MRSA's cell membrane, causing leakage and cell death. This mechanism proved effective even against dormant MRSA, a characteristic that makes the superbug particularly challenging to eradicate.

Further research indicated that Candesartan cilexetil enhances the efficacy of conventional antibiotics like gentamicin. When combined, they achieve a stronger effect at lower doses than either treatment alone. Given that the drug is already approved and widely available, it presents an attractive candidate for further investigation, potentially offering a cost-effective solution to a growing global health threat.

MRSA infections are a significant concern, causing tens of thousands of severe cases and thousands of deaths annually in the United States alone. The development of new antibiotics has lagged behind the rise of resistant microbes, which were responsible for over 1.27 million deaths globally in 2019. Researchers are now working to refine Candesartan cilexetil and are initiating discussions for human trials to bring this promising treatment from the lab to patients.